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Our recent studies suggest a unique role of p53 during the early stage of cancer development. How-
ever, how p53 activation is regulated during TPA treatment remains elusive. We used murine skin
epidermal JB6 promotion-sensitive (P+) and promotion resistant (P) cells to observe differential
expression of PTEN during TPA-induced p53 activation. Total PTEN expression was decreased in only
P+ cells. Nuclear expression of PTEN increased and complex formation between PTEN and p53
occurred in P+ cells treated with TPA. Knocking down PTEN expression via siRNA inhibited TPA-
induced Bax expression. Similar effects were seen with the p53 inhibitor, piﬁthrin-alpha. Cells that
were transfected with siRNA to PTEN exhibited enhanced tumorigenicity. Our ﬁndings suggest PTEN
mediates TPA-induced p53 activation.
Structured summary of protein interactions:
PTEN and p53 colocalize by ﬂuorescence microscopy (View interaction)
PTEN physically interacts with p53 by anti bait coimmunoprecipitation (View Interaction: 1, 2)
PTEN and p53 colocalize by cosedimentation in solution (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction germline mutations in Pten are associated with hereditary cancerThe short-lived, p53 tumor suppressor protein plays a major
role in rapidly responding to cellular stress by transcriptionally
activating genes involved in cell cycle control, DNA repair, senes-
cence, and apoptosis [1]. Slightly more than 50% of human cancers
contain mutations in the TP53 gene. Mice carrying a homozygous
p53 null mutation are more susceptible to cancer [2]. p53 is pri-
marily regulated by Mdm2, a proto-oncogene E3 ubiquitin ligase
that promotes rapid p53 proteosomal degradation [3,4]. However,
various upstream signaling molecules regulate p53 activation fol-
lowing cellular stress. Akt is known to phosphorylate Mdm2 at
Ser166 and Ser186 promoting nuclear localization of Mdm2 where,
it induces degradation and suppresses the function of p53 [5–7]
PTEN (phosphatase and tensin homologue deleted on chromosome
10), a dual protein and lipid phosphatase, exhibits its tumor sup-
pressor activity by antagonizing the phosphatidylinositol-3-kinase
(PI3K/Akt) pathway. PTEN is frequently mutated and/or deleted in
most human cancers. While somatic mutations in Pten exist,chemical Societies. Published by E
Pharmacology, Toxicology &
ciences Center, 1501 Kings
5 7857.syndromes, such as Cowden disease [8]. In in vitro studies, cells
containing mutant PTEN are resistant to apoptotic stimuli such as
tumor necrosis factor a stimuli, osmotic shock and heat treatment,
and UV irradiation [10].
Our recent studies suggest a unique role of p53 during the early
stage of cancer development [14]. However, how p53 activation is
regulated during TPA treatment remains elusive. Herein, we ana-
lyzed PTEN involvement in TPA-induced p53 activation, using
Western blot analysis, siRNA transfection and the soft agar trans-
formation assay to assess effects on tumorigenicity. Our major
aims were to understand whether PTEN expression is required
for TPA-induced p53 activation, and whether knockdown of PTEN
expression altered protein expression of pro-apoptotic p53
transcriptional targets and affected tumorigenicity.
2. Materials and methods
Cell line, reagents and treatment-Murine skin epidermal JB6
response variants: stably responsive JB6 (P+, CL41 [14]) and non-
responsive JB6 (P, CL30-7b) to tumor promoter-induced transfor-
mation were purchased from American Type Culture Collection.
Cells were grown in EMEM medium supplemented with 4% fetal
bovine serum, 2 mM of L-glutamine, 50 lg/ml penicillin andlsevier B.V. All rights reserved.
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a 100 lM stock solution in dimethylsulfoxide (DMSO). The TPA
stock solution was diluted directly in the cell culture medium, with
the resulting concentration being 100 nM [14].
siRNA Transfection-Cells were seeded 2  105 cells per well in
six-well tissue culture plates. The cells were transfected according
to the manufacturer’s instructions. Immediately following, the
transfection mixture was removed and replaced with 2 ml of 1
normal growth medium. The cells were incubated for an additional
24 h and assayed via Western blot analysis. Fluorescein conjugated
control siRNA (sc-36869, Santa Cruz Biotechnology) was used to
monitor transfection efﬁciency.
Anchorage-independent growth assay in soft agar-Assays were
carried out in six-well plates as previously described [14]. For each
well, the bottom layer consisted of 3.5 ml of 0.5% agar in EMEM
(10% FBS). A total of 1  105 JB6 cells, suspended in 0.75 ml of
0.33% agar in EMEM (10% FBS), were layered on top and incubated
for 7 days for both transfection and piﬁthrin-alpha soft agar exper-
iments. Both layers were supplemented with either TPA (5 nM) or
DMSO was used as a vehicle control. To assess the effects of piﬁth-
rin-alpha on tumorigenicity, piﬁthrin-alpha alone (1 lM) or the
treatment combination (piﬁthrin-alpha [1 lM] + TPA [5 nM]) were
used, in addition to the previously mentioned treatments. The col-
onies were counted manually after Neutral Red staining. The trans-
formation response was expressed as the number of colonies
formed per 105 cells per well.
Preparation of whole cell lysate of JB6 cells-JB6 cells were col-
lected by centrifugation and resuspended in RIPA buffer (50 mM
Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1%
Triton 100) supplemented with the protease inhibitor cocktail
(5 lg/ml each of pepstatin, leupeptin, and aprotinin), sonicated
(Sonic Dismembrator Model 100, scale 2, Fisher Scientiﬁc), incu-
bated on ice for 3 min, and centrifuged at 18000g for 20 min.
The supernatant was collected as the whole cell lysate.
Isolation of nuclear fraction from skin cells-Cells were collected
in ice cold PBS and suspended in 400 ll of buffer A [10 mmol/l
HEPES-KOH with 1.5 mmol/l MgCl2, 10 mmol/l KCl, 0.2 mmol/l
phenylmethylsulfonyl ﬂuoride, and 5 lmol/l DTT] containing
protease inhibitors (5 lg/ml each of pepstatin, leupeptin and
aprotinin). Samples were incubated in buffer A on ice for
15 min. Twenty-ﬁve microliters of 10% NP-40 were added and
the sample was vortexed vigorously for 15 s. The lysate was cen-
trifuged at 14,000 rpm for 1 min. The resulting pellet was dis-
solved in 100 ll of buffer B [20 mmol/l HEPES-KOH with
1.5 mmol/l MgCl2, 420 mmol/l NaCl, 35% glycerol, 0.2 mmol/l
phenylmethylsulfonyl ﬂuoride, 5 lM of DTT, and 0.2 mmol/l
EDTA (pH 8.0)] containing the above proteinase inhibitors. The
sample was incubated on ice for 30 min and centrifuged at
12,000 rpm for 3 min. The supernatant was labeled as nuclear
extract and stored at 80 C.
Immunoprecipitation-One hundred micrograms of the whole cell
lysate from JB6 cells treated with either DMSO or TPA [100 nM] for
24 h were incubated with rabbit IgG (Jackson ImmunoResearch,
Inc) and 20 ll of Protein A/G PLUS-Agarose conjugate (Santa Cruz
Biotechnology) at 4 C for 30 min. The lysate was centrifuged at
2,500 rpm for 5 min at 4 C to preclear the lysate. The precleared ly-
sate was incubated with 2 lg of anti-p53 (FL-393, Santa Cruz Bio-
technology) for 1 h at 4 C, followed by the addition of 20 ll
Protein A/G PLUS-Agarose conjugate overnight. The immunoprecip-
itates were collected by centrifugation at 2,500 rpm for 5 min at
4 C. After washing 4 times with RIPA buffer, the samples were
immediately analyzed by Western blot analysis.
Immunoﬂuorescent staining of PTEN-Ten thousand JB6 cells were
seeded in eight-well Lab-Tek chamber slides w/ cover (Nalge Nunc
International, Naperville, IL) in 400 ll medium per well and incu-
bated overnight. Twenty-four hours after plating, cells were incu-bated with TPA 100 nM or equivolume DMSO for 24 h.
Afterwards, the treatment was removed. The cells were washed
with cold PBS and ﬁxed in 10% formaldehyde solution for 15 min
at room temperature. After rinsing with cold PBS, cells were per-
meabilized with 1% Triton X-100 for 10 min at room temperature.
Cells were washed with PBS and anti-p53 antibody (FL-393, Santa
Cruz Biotechnology) was added (1:32 dilution) and incubated at
37 C for 1 h followed by washing with PBS and incubation with
an anti-rabbit IgG-TRITC (Jackson ImmunoResearch Laboratories,
Inc.) for 1 h. After the removal of antibodies, anti-PTEN antibody
(MAB-4037, Millipore) was added (1:32 dilution) and incubated
at 37 C for 1 h followed by incubation with anti-mouse IgG-FITC
(Sigma 1:32 dilution) for 1 h. After removal of antibodies, the cells
were rinsed with PBS and mounted with DPX mounting medium
(Electron Microscopy Sciences). Fluorescence was immediately ob-
served using a wide ﬁeld inverted microscope (Nikon Eclipse
TE300).
Western blot analysis-The whole cell lysate prepared from JB6
cells was used to detect sufﬁcient knockdown of PTEN in siRNA
experiments; Bax and p53 expression following TPA and piﬁth-
rin-alpha treatments, and immunoprecipitation studies. Twenty
micrograms of protein samples were separated on a 10% SDS–
PAGE gel and transferred to nitrocellulose membrane. Ponceau
S staining was used to monitor the uniformity of the transfer.
The membrane was blocked in Blotto (5% milk, 10 mM Tris–
HCl [pH 8.0], 150 mM NaCl and 0.05% Tween-20) for 1 h at room
temperature. Anti-PTEN antibody (MAB4037, Millipore, Temecu-
la, CA); or anti-p53 antibody (FL-393, Santa Cruz Biotechnology)
or anti-Bax antibody (P-19, Santa Cruz Biotechnology) were
added in 1:500 dilutions and the membrane was incubated for
2 h at room temperature. After washing, the membrane was
incubated with the respective horseradish peroxidase conjugated
secondary antibodies (Santa Cruz Biotechnology) at a 1:1000
dilution. For loading controls, succinate dehydrogenase subunit
B (SDHB, FL280, Santa Cruz Biotechnology); proliferating cell nu-
clear antigen (PCNA, sc-56, Santa Cruz Biotechnology) and glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH, sc-32233,
Santa Cruz Biotechnology) were used. The antibody bands were
visualized by the enhanced chemiluminescent detection system
(ECL, Amersham). Image J 1.38x Software was used for densito-
metric analysis for protein bands obtained by Western blot anal-
ysis, and the ratio of density of the loading control was plotted
and analyzed using GraphPad Prism 3 Software.
Detection of ROS-The production of ROS was assayed using
DCF-DA as a substrate. Brieﬂy, ﬁve thousand cells were seeded
in a 96-well plate and incubated overnight. For the piﬁthrin-al-
pha experiment, cells were pre-treated with 5 nM piﬁthrin-alpha
for 30 min. The medium was replaced with fresh medium con-
taining either 100 nM TPA or DMSO as a vehicle control and
incubated for 15 min. Cells were washed with PBS (pH 7.4)
and incubated 15 min with fresh medium containing 10 lM
DCFH-DA (Molecular Probes, Eugene, OR) at 37 C. DCFH-DA
was oxidized by ROS to the highly ﬂuorescent 20, 70-dichloroﬂu-
orescein (DCF). The ﬂuorescence was then read at excitation/
emission of 488/525 nm for DCF with a Spectra Max Gemini
plate reader from Molecular Devices. The ﬂuorescence from cells
only (no dye added) was used to subtract the sample value from
each corresponding well.
Caspase 3 Activity Assay-Total cell lysate was prepared and ca-
pase 3 activity was detected for each sample treatment group
using the CasPASE apoptosis assay kit (G-Biosciences, St. Louis,
MO) following the manufacturer’s instructions.
Statistical analysis-Statistical analysis was performed using one-
way ANOVA (for multiple group comparison) followed by the New-
man–Keuls post-test. p < 0.05 was judged to be signiﬁcantly
different.
Fig. 1. TPA induced the PTEN-p53 interaction in JB6 P+ cells. (A) Total PTEN expression levels in JB6 P+ and P cells after treating with DMSO as the vehicle control or TPA
(100 nM) for 1 and 24 h. Total cell lysate was used for the experiment. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (B) PTEN-p53
interaction in JB6 P+ cells. JB6 P+ cells were treated with DMSO (equivolume) or TPA (100 nM) for 24 h. The JB6 cell lysate was subjected to immunoprecipitation (IP) with
anti-PTEN or anti-p53 antibody and then immunoblotted (IB) with the corresponding antibodies. Normal immunoglobulin (IgG) was used as a control for
immunoprecipitation. (C) PTEN-p53 interaction in JB6 P cells. JB6 P cells were treated with DMSO (equivolume) or TPA (100nM) for 24 h. The JB6 cell lysate was
subjected to immunoprecipitation (IP) with anti-PTEN or anti-p53 antibody and then immunoblotted (IB) with the corresponding antibodies. Normal immunoglobulin (IgG)
was used as a control for immunoprecipitation. Ctrl: DMSO (vehicle control); T/1 h: TPA treatment for 1 h. T/24 h: TPA treatment for 24 h.
Fig. 2. Immunoﬂuorescent staining of p53 and PTEN in JB6 P+ and P cells. Ten thousand JB6 cells were seeded in eight-well Lab-Tek chamber slides w/ cover (Nalge Nunc
International, Naperville, IL) in 400 ll medium per well and incubated overnight. Twenty-four hours after plating, cells were incubated with TPA 100 nM or equivolume
DMSO for 24 h. Afterwards, the treatment was removed. The cells were washed with cold PBS and ﬁxed in 10% formaldehyde solution for 15 min at room temperature. After
rinsing with cold PBS, cells were permeabilized with 1% Triton X-100 for 10 min at room temperature. Cells were washed with PBS and an anti-p53 (FL393, Santa Cruz) or
anti-PTEN antibody (MAB-4037, Millipore) was added (1:32 dilution) and incubated at 37 C for 1 h followed by incubation with anti-rabbit IgG-TRITC (Sigma, 1:32 dilution,
for p53 staining) anti-mouse IgG-FITC (Sigma, 1:32 dilution, for PTEN staining) for 1 h. After removal of antibodies, the cells were rinsed with PBS and mounted with DPX
mounting medium with DAPI (Electron Microscopy Sciences). Fluorescence was immediately observed using a wide ﬁeld inverted microscope (Nikon Eclipse TE300). TPA
(100 nM) induced PTEN nuclear localization at the 24 h time point. Overlay, overlay of p53 and PTEN staining.
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TPA treatment induced the PTEN-p53 interaction only in JB6 P+ tu-
mor promotable mouse skin epidermal cells. To determine whether
PTEN activation is involved in TPA-induced tumor promotion, we
assessed PTEN levels in whole cell lysate of JB6 cell variants, both
promotable P+ and non-promotable P cells. The JB6 cell system
is a well-established in vitro model and has shown predictive
validity when compared to in vivo models such as mouse models
of skin carcinogenesis and a human keratinocyte progression mod-
el [15–22]. Following TPA treatment for 1 and 24 h (Fig. 1A), PTEN
expression in whole cell lysate decreased following TPA treatment
only in P+ cells (the decreases in PTEN expression levels were
maintained throughout the 24-h time course, data not shown),
which was not seen in the P counterpart.
PTEN promotes stabilization, acetylation and tetramerization of
p53 in the nucleus through phosphatase-dependent and -indepen-
dent mechanisms [23]. We next inquired whether TPA induces an
interaction between PTEN and p53 in JB6 P+ and P cells as a
mechanism of p53 activation. We treated P+ and P cells with
TPA for 24 h, analyzed whole cell lysate using immunoprecipita-
tion with anti-PTEN and anti-p53 antibodies; and utilized Western
blot analysis to detect protein expression with the corresponding
antibodies. As shown in Fig. 1B, TPA induced the PTEN-p53 interac-
tion only in JB6 P+ cells. Surprisingly, this interaction was not de-
tected in promotion resistant JB6 P cells (Fig. 1C), suggesting
that the PTEN-p53 interaction is correlated with early stage tumor
promotion.
TPA treatment can induce p53 nuclear translocation and trans-
activation in JB6 P+ cells. We utilized cellular fractionation and
Western blot analysis to determine if TPA could induce concurrentFig. 3. PTEN-knockdown enhanced TPA-induced skin cell transformation by modulation
cytoplasmic levels of p53 and PTEN. TPA (100 nM) induced both p53 and PTEN nuclear
control. (B) JB6 P+ cells were subjected to transient transfection of siRNA to PTEN and an
cell lysate was used for the experiment. Succinate dehydrogenase subunit B (SDHB) ser
transformation. Neoplastic transformation was assessed via the soft agar assay. Colonies w
105 cells per well. Ctrl-siRNA: control siRNA; si-PTEN: siRNA targeting PTEN; Ctrl: DMS
groups; ⁄⁄⁄, signiﬁcantly different from TPA Ctrl-siRNA group. p < 0.005 considered signi
capase 3 activity was detected for each sample treatment group using the CasPASE
instructions. ⁄⁄, signiﬁcantly different from Ctrl (DMSO) treated groups; ⁄⁄⁄, signiﬁcantly d
DMSO (vehicle control); T/1 h: TPA treatment for 1 h; T/24 h: TPA treatment for 24 h.PTEN nuclear localization in promotable P+ or non-promotable P-
cells. As shown in Fig. 2, in P+ cells, TPA treatment caused de-
creased protein expression levels of PTEN in the cytosol whereas
increased levels of PTEN in the nucleus; concurrently, TPA treat-
ment caused increased p53 protein levels in both the cytosol and
nucleus. In P cells, TPA treatment did not affect PTEN protein
expression levels or induce PTEN nuclear translocation, and it did
not induce p53 expression, either. Consistent with these results,
Western blot analysis revealed that TPA treatment induced in-
creases in both nuclear and cytoplasmic p53; whereas it decreased
cytoplasmic but increased nuclear PTEN levels at the 24-h time
point in P+ cells (Fig. 3A). Previously, we have shown that TPA
induces higher levels of ROS in JB6 P+ cells when compared to
P cells [14]. Thus, our data suggest that PTEN and p53 nuclear
translocation are redox-regulated in promotion-sensitive P+ cells.
Decreased p53 transcriptional activity via PTEN knockdown en-
hanced TPA-induced skin cell transformation in tumor promotion
sensitive JB6 P+ cells
To determinewhether TPA-induce p53 activation is regulated by
PTEN, we measured the downstream p53 transcriptional target Bax
in JB6 (P+) cells following siRNAPTENknockdown. Interestingly, Bax
protein levels were signiﬁcantly decreased (Fig. 3B), suggesting that
knocking down PTEN protein expression decreases TPA-induce p53
activation. To further assess the effects of PTEN expression on p53
activation, we utilized the soft agar transformation assay (Fig. 3C).
Knocking down PTEN via siRNA enhanced TPA induced colony for-
mation. In addition, PTEN knockdown suppressed TPA-induced cas-
pase 3 activation. Therefore, our results suggest that PTEN plays a
regulatory role in TPA-mediated p53 activation, decreasing p53
apoptotic stimuli (Fig. 3B andD) andenhancingTPA-induced tumor-
igenicity following PTEN knockdown.of p53 nuclear transactivation and -mediated caspase 3 activity. (A) Nuclear and
localization at the 24 h time point. Nuclear marker, Lamin B, was used as a loading
alyzed for PTEN, p53 and Bax expression following TPA (100 nM) treatment. Whole
ved as a loading control. (C) PTEN knockdown enhanced TPA-mediated neoplastic
ere counted following Neutral red staining and expressed as number of colonies per
O (vehicle control); TPA: 5 nM. ⁄⁄, signiﬁcantly different from Ctrl (DMSO) treated
ﬁcantly different. (D) Relative caspase 3 activity. Total cell lysate was prepared and
apoptosis assay kit (G-Biosciences, St. Louis, MO) following the manufacturer’s
ifferent from TPA Ctrl-siRNA group. p < 0.005 considered signiﬁcantly different. Ctrl:
Fig. 4. Piﬁthrin-alpha suppressed p53 transcriptional activity and reduced TPA-induced tumorigenicity. (A) Western blot analysis of p53 and Bax protein expression levels.
JB6 P+ cells were treated with DMSO or TPA (100 nM) for 24 h; Piﬁthrin-alpha (5 lM) for 30 min alone; or Piﬁthrin-alpha (5 lM) for a 30-min pre-treatment followed by TPA
for 24 h. The whole cell lysate was used. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (B) Neoplastic transformation was assessed via
the soft agar assay. All treatments were applied directly to both layers of soft agar. (C) Colonies were counted following Neutral red staining and expressed as number of
colonies per 105 cells per well. (D) Piﬁthrin-alpha decreased TPA-induced ROS generation. The production of ROS was assayed using DCF-DA as a substrate. Five thousand cells
were seeded in a 96-well plate and incubated overnight. For the piﬁthrin-alpha experiment, cells were pre-treated with 5 nM piﬁthrin-alpha for 30 min. The medium was
replaced with fresh medium containing either 100 nM TPA or DMSO as a vehicle control and incubated for 15 min. Cells were washed with PBS (pH 7.4) and incubated 15 min
with fresh medium containing 10 lM DCFH-DA (Molecular Probes, Eugene, OR) at 37 C. DCFH-DA is oxidized by ROS to the highly ﬂuorescent 20 , 70-dichloroﬂuorescein
(DCF). The ﬂuorescence was then read at excitation/emission of 488/525 nm for DCF with a Spectra Max Gemini plate reader from Molecular Devices. The ﬂuorescence from
cells only (no dye added) was used to subtract the sample value from each corresponding well. Ctrl: DMSO (vehicle control); TPA: 5 nM; PIF: piﬁthrin-alpha (1 lM) for soft
agar; (5 lM) for Western blot analysis; P + T: treatment combination of piﬁthrin-alpha 30-min pre-treatment followed by TPA 24-h treatment. ⁄, signiﬁcantly different from
Ctrl (DMSO) treatment group; ⁄⁄, signiﬁcantly different from Ctrl (DMSO) treatment group and TPA treatment. p < 0.005 considered signiﬁcantly different.
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p53 is a known transcription factor that induces the expression
of genes that play a central role in cellular apoptosis, cell cycle
arrest and DNA repair. To further validate the role of p53 nuclear
localization in TPA-mediated apoptosis, we utilized the p53 inhib-
itor, piﬁthrin-alpha. When treated with piﬁthrin-alpha, the protein
levels of the p53 transcriptional target, Bax, were signiﬁcantly re-
duced and could not be rescued by TPA treatment (Fig. 4A), sug-
gesting that p53 transcriptional regulation is necessary in
regulating TPA-mediated pro-apoptotic mechanisms. Interestingly,
piﬁthrin-alpha blocked TPA-induced decreases in PTEN expression
levels. We performed the soft agar assay treating cells with either
DMSO, TPA (5 nM) alone, piﬁthrin-alpha (1 lM) alone or with a
treatment combination of piﬁthrin-alpha (1 lM) plus TPA (5 nM).
Interestingly, when treated with both piﬁthrin-alpha and TPA, we
observed a signiﬁcant decrease in TPA-induced neoplastic transfor-
mation (Fig. 4B and C), suggesting that p53 activation plays a sig-
niﬁcant role in contributing to skin transformation. To further
examine the suppressive mechanism of piﬁthrin-alpha treatment
during TPA-mediated apoptosis, we measured intracellular ROS
generation using 20,70-dichloroﬂuorescin–diacetate (DCFH-DA) as
a substrate. JB6 cells were treated with 100 nM TPA or DMSO as
a control and incubated for 10 min. For the piﬁthrin-a treatment,
cells were treated with piﬁthrin- a for 30 min. Piﬁthrin- a was
either replaced with fresh media (piﬁthrin- a alone treatment
group) or replaced with medium containing TPA 100 nM and incu-
bated for an additional 10 min. As shown in Fig. 3D, cells pre-
treated with piﬁthrin-alpha showed a signiﬁcant decrease in
TPA-mediated ROS generation, suggesting that piﬁthrin-alpha de-
layed TPA-induced skin cell transformation in JB6 P+ cells by
reducing intracellular ROS production.4. Discussion
It is known that p53 is mutated in more than 50% of human tu-
mors, with the remaining tumors consisting of wild-type p53 with
defects in the apoptotic p53 signaling pathway [24]. Thus, restor-
ing p53 activation is complex and has recently become an impor-
tant target in drug development due to its integral role in
determining cellular fate.
In the two-stage skin carcinogenesis model, TPA treatment is
also directly correlated with an increase in p53 nuclear transloca-
tion and expression of its transcriptional targets, such as Bax, sug-
gesting that regulation of p53 transcriptional activity may be
another potential therapeutic target [25–27]. Interestingly,
whether other tumor suppressor proteins play a role in mediating
TPA-induced p53 activation remains unresolved. Nonetheless,
Freeman and colleagues showed that p53 transactivation can be
regulated by other tumor suppressors such as PTEN [23].
Herein, we found that TPA treatment induces nuclear localiza-
tion of both PTEN and p53. Several studies have demonstrated
that PTEN nuclear localization is a dynamic process associated
with cell cycle and cellular functions [30]. In this study, we
provide the ﬁrst evidence that PTEN mediates TPA-induced p53
downstream target genes such as Bax in murine JB6 P+ skin
epidermal cells. In PTEN siRNA knockdown cells following TPA
treatment, the downstream p53 transcriptional target, Bax was
signiﬁcantly suppressed. These results strengthens the idea that
p53 transactivation is dependent on PTEN expression. Given the
similarity between the results of piﬁthrin-alpha mediated inhibi-
tion of p53 transcriptional activity and those observed following
PTEN knockdown, we conclude that PTEN-mediated p53 activa-
tion may be a common mechanism utilized to regulate TPA-
induced p53 activation and apoptosis.
D. Robbins et al. / FEBS Letters 586 (2012) 4108–4113 4113In summary, we have shown that TPA can enhance PTEN nucle-
ar accumulation; and that by knocking down PTEN, apoptosis is
suppressed. In addition, we have shown that TPA-induced p53
activation is not only mediated by ROS generation, but also by
the tumor suppressor protein, PTEN that complexes with p53
and enhances its transcriptional activation, as evidenced by Bax.
Therefore, developing small molecules that target mediators of
p53 activation such as PTEN may potentially be a novel approach
to restoring wild-type p53 activation in drug development.
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